What are the nursing skills, procedures, and device considerations for transcatheter aortic valve replacement (TAVR), including system relevance, indications, contraindications, baseline assessment, required supplies, pre‑procedure steps, intra‑procedure steps, post‑procedure care, normal parameters, expected physiologic response, alarms/troubleshooting, complications with nursing interventions, red‑flag signs, ongoing reassessment, and documentation?

TAVR: Comprehensive Nursing Guide

System Overview

TAVR is a cardiovascular procedure involving the transcatheter replacement of a diseased aortic valve, primarily managed within the cardiac catheterization laboratory or hybrid operating room with multidisciplinary team involvement. 1

---

Indications

• Severe symptomatic aortic stenosis in patients at intermediate to high surgical risk or deemed inoperable 2
• Patients with extensive comorbidities making sternotomy and cardiopulmonary bypass prohibitively high risk 3
• Expanding indications now include lower-risk surgical candidates based on evolving evidence 2
• Off-label use for severe aortic regurgitation with dedicated devices, though surgical aortic valve replacement remains standard 4

---

Contraindications

• Absolute contraindications:

  • Inability to tolerate anticoagulation/antiplatelet therapy 5
  • Active endocarditis 5
  • Intracardiac thrombus 5
  • Severe peripheral vascular disease preventing catheter access 3

• Relative contraindications:

  • Unfavorable aortic valve anatomy (excessive calcification, inadequate anchoring zones) 5, 6
  • High risk of coronary obstruction based on CT assessment 6
  • Severe left ventricular dysfunction with poor prognosis 5

---

Baseline Assessment Prior to Procedure

Comprehensive cardiovascular and multisystem evaluation is mandatory:

• Cardiac assessment:

  • Transthoracic echocardiography (TTE) to confirm severe aortic stenosis severity 2
  • Transesophageal echocardiography (TEE) and 3-dimensional imaging for valve anatomy 1
  • CT angiography for aortic annulus sizing, coronary anatomy, and vascular access planning 6
  • Cardiac catheterization to assess coronary artery disease 7

• Functional status:

  • New York Heart Association (NYHA) functional class 7
  • Six-minute walk test or equivalent functional capacity assessment 7
  • Frailty assessment using validated tools 7

• Vascular assessment:

  • CT angiography of iliofemoral vessels to determine access route (transfemoral vs. alternative access) 3
  • Peripheral vascular disease screening 3

• Laboratory evaluation:

  • Complete blood count, coagulation profile (PT/INR, aPTT) 8
  • Comprehensive metabolic panel including renal function (creatinine, eGFR) 8
  • Liver function tests 8
  • Brain natriuretic peptide (BNP) or NT-proBNP 8

• Neurological screening:

  • Baseline cognitive assessment 5
  • Stroke risk evaluation 5

• Multidisciplinary Heart Valve Team evaluation:

  • Documentation of evaluation by both cardiac surgeon and cardiologist with TAVR/SAVR expertise 1
  • Shared decision-making process incorporating patient preference 1

---

Supplies

Procedural equipment:

• Transcatheter aortic valve prosthesis (device-specific: balloon-expandable or self-expanding) 3
• Delivery catheter system 3
• Guidewires (stiff and soft) 3
• Vascular access sheaths (large bore, typically 14-20 French) 3
• Balloon valvuloplasty catheter 3
• Temporary pacemaker and leads 3
• Vascular closure devices 3

Imaging:

• Fluoroscopy with advanced imaging capabilities 1
• TEE probe and equipment 1
• Contrast media 8

Medications:

• Anticoagulation (heparin) 5
• Antiplatelet agents (aspirin, P2Y12 inhibitor) 5
• Vasopressors/inotropes (norepinephrine, epinephrine, dopamine) 8
• Rapid ventricular pacing capability 3
• Emergency resuscitation medications 8

Monitoring:

• Invasive arterial line 8
• Central venous access 8
• Continuous ECG monitoring 8
• Pulse oximetry 8

---

Pre-Procedure Steps

Patient preparation:

• NPO status: Minimum 6-8 hours for solids, 2 hours for clear liquids per institutional protocol 8

• Medication management:

  • Continue aspirin and initiate P2Y12 inhibitor (clopidogrel 300-600 mg loading dose) per protocol 5
  • Hold anticoagulation per institutional guidelines with bridging if indicated 5
  • Continue beta-blockers and other cardiac medications 8

• Vascular access site preparation:

  • Bilateral groin shaving and antiseptic preparation 8
  • Mark femoral pulses bilaterally 8

• Informed consent verification:

  • Confirm signed consent for TAVR, anesthesia, blood products, and potential complications 7

• Baseline vital signs and neurological assessment:

  • Document baseline mental status, motor/sensory function 5
  • Establish baseline ECG rhythm (identify pre-existing conduction abnormalities) 5

• IV access:

  • Establish at least two large-bore peripheral IVs 8

• Anesthesia preparation:

  • General anesthesia or conscious sedation per institutional protocol 3
  • TEE probe insertion if general anesthesia 3

---

Procedure Steps

Intra-procedural nursing responsibilities:

1. Vascular access establishment:

   • Assist with femoral artery access (transfemoral approach) or surgical exposure (transapical/transaortic) 3
   • Monitor for vascular complications (bleeding, hematoma, dissection) 3

2. Temporary pacemaker placement:

   • Assist with transvenous pacemaker lead insertion via femoral or internal jugular vein 3
   • Verify capture threshold and set pacing parameters 3

3. Balloon aortic valvuloplasty:

   • Prepare for rapid ventricular pacing (typically 180-220 bpm) to reduce cardiac output during balloon inflation 3
   • Monitor hemodynamics during apnea and pacing 3

4. Valve deployment:

   • Assist with valve positioning under fluoroscopic and TEE guidance 3
   • Prepare for rapid ventricular pacing during valve expansion 3
   • Monitor for immediate complications (valve embolization, coronary obstruction, annular rupture) 5

5. Post-deployment assessment:

   • TEE evaluation for paravalvular leak, valve position, and coronary flow 5
   • Hemodynamic assessment (aortic valve gradient, cardiac output) 5

6. Vascular closure:

   • Assist with vascular closure device deployment or surgical repair 3
   • Apply manual compression if required 3

---

Post-Procedure Care

Immediate post-procedure (0-24 hours):

• Hemodynamic monitoring:

  • Continuous arterial blood pressure monitoring (target MAP >65 mmHg) 8
  • Continuous ECG monitoring for arrhythmias and conduction disturbances 5
  • Hourly vital signs for first 4 hours, then per protocol 8

• Vascular access site management:

  • Assess access site every 15 minutes for first hour, then hourly 8
  • Monitor for bleeding, hematoma, pseudoaneurysm, retroperitoneal hemorrhage 5
  • Assess distal pulses, capillary refill, and limb temperature 8
  • Maintain bed rest with leg immobilization per institutional protocol (typically 2-6 hours) 8

• Neurological assessment:

  • Perform neurological checks every hour for first 4 hours, then every 4 hours 5
  • Assess for signs of stroke (facial droop, arm drift, speech changes) 5

• Cardiac rhythm monitoring:

  • Continuous telemetry for 24-48 hours minimum 5
  • Monitor for new-onset heart block, atrial fibrillation, ventricular arrhythmias 5
  • Temporary pacemaker management if placed (assess capture, monitor for need for permanent pacemaker) 3

• Fluid management:

  • Monitor urine output (target >0.5 mL/kg/hr) 8
  • Assess for acute kidney injury (contrast-induced nephropathy) 5
  • Maintain euvolemia (avoid both hypovolemia and fluid overload) 8

• Pain management:

  • Assess pain using validated scale 8
  • Administer analgesics per protocol (avoid NSAIDs due to antiplatelet therapy) 8

• Anticoagulation/antiplatelet therapy:

  • Resume or initiate dual antiplatelet therapy (aspirin + P2Y12 inhibitor) per protocol 5
  • Monitor for bleeding complications 5

---

Normal Parameters and Acceptable Variations

Hemodynamic parameters:

• Blood pressure: Systolic 90-140 mmHg, MAP >65 mmHg 8
• Heart rate: 60-100 bpm (may be higher immediately post-procedure) 8
• Cardiac output/index: Within normal limits for patient baseline 8
• Aortic valve gradient: Significant reduction from baseline (mean gradient <20 mmHg is typical) 5

Acceptable variations:

• Transient hypotension requiring vasopressor support (common immediately post-procedure) 8
• Mild paravalvular regurgitation (trace to mild) 5
• Transient arrhythmias (atrial fibrillation, premature ventricular contractions) 5

---

Expected Physiological Response

• Immediate improvement in hemodynamics: Reduced aortic valve gradient, improved cardiac output 5
• Symptom relief: Gradual improvement in dyspnea, fatigue, and functional capacity over days to weeks 2
• Improved quality of life: Documented in clinical trials comparing TAVR to medical management 3
• Reduced heart failure symptoms: Decreased BNP/NT-proBNP levels over time 8

---

Alarms/Troubleshooting

Hypotension:

• Causes: Bleeding (vascular access site, retroperitoneal), cardiac tamponade, severe paravalvular regurgitation, arrhythmias 5
• Interventions: Assess access site, obtain STAT echocardiogram, administer fluid bolus or vasopressors, notify physician immediately 8

Bradycardia/heart block:

• Causes: Conduction system injury from valve deployment (common with self-expanding valves) 5
• Interventions: Initiate temporary pacing if available, prepare for permanent pacemaker placement (occurs in 10-30% of patients) 5

Acute neurological changes:

• Causes: Embolic stroke, intracranial hemorrhage 5
• Interventions: Activate stroke protocol, obtain STAT CT head, notify physician and neurology immediately 5

Vascular access site bleeding:

• Causes: Inadequate hemostasis, anticoagulation, vascular injury 5
• Interventions: Apply manual pressure, assess for retroperitoneal hemorrhage (back pain, hypotension, falling hemoglobin), obtain STAT CT abdomen/pelvis if suspected 5

Acute kidney injury:

• Causes: Contrast-induced nephropathy, hypotension, atheroemboli 5
• Interventions: Monitor urine output and creatinine, ensure adequate hydration, avoid nephrotoxic agents 5

---

Complications and Nursing Interventions

Major complications:

1. Paravalvular leak (PVL):

   • Incidence: Reduced with newer valve designs but remains a concern 5
   • Assessment: TEE evaluation, auscultation for diastolic murmur 5
   • Intervention: Mild PVL may be observed; moderate-severe requires physician evaluation for potential valve-in-valve procedure 5

2. Stroke/transient ischemic attack:

   • Incidence: 2-5% 5
   • Prevention: Cerebral protection devices (controversial efficacy), meticulous technique 5
   • Intervention: Immediate neurological assessment, activate stroke protocol, consider thrombolysis or thrombectomy per neurology 5

3. Vascular complications:

   • Incidence: 5-15% (bleeding, dissection, pseudoaneurysm, limb ischemia) 5
   • Assessment: Access site inspection, distal pulse checks, hemoglobin monitoring 5
   • Intervention: Vascular surgery consultation, potential surgical repair or endovascular intervention 5

4. Conduction disturbances/complete heart block:

   • Incidence: 10-30%, higher with self-expanding valves 5
   • Assessment: Continuous ECG monitoring, assess for symptomatic bradycardia 5
   • Intervention: Temporary pacing, permanent pacemaker implantation if persistent (typically within 48-72 hours) 5

5. Cardiac tamponade:

   • Incidence: 1-2% (annular rupture, ventricular perforation) 5
   • Assessment: Hypotension, elevated jugular venous pressure, muffled heart sounds, pulsus paradoxus 5
   • Intervention: STAT echocardiogram, emergent pericardiocentesis or surgical intervention 5

6. Coronary obstruction:

   • Incidence: <1%, higher risk with low coronary ostia or valve-in-valve procedures 6
   • Assessment: ST-segment elevation on ECG, hemodynamic collapse 5
   • Intervention: Emergent coronary angiography and percutaneous coronary intervention or surgical revascularization 5

7. Acute kidney injury:

   • Incidence: 10-20% 5
   • Assessment: Rising creatinine, decreased urine output 5
   • Intervention: Optimize hemodynamics, avoid nephrotoxins, consider renal replacement therapy if severe 5

---

Red Flags / When to Escalate

Immediate physician notification required:

• Hemodynamic instability: Systolic BP <90 mmHg despite interventions, MAP <65 mmHg 8
• Acute neurological changes: New focal deficits, altered mental status, seizure 5
• Severe bradycardia/heart block: Heart rate <40 bpm, symptomatic bradycardia, new complete heart block 5
• Chest pain with ECG changes: ST-segment elevation or depression suggesting coronary obstruction or myocardial infarction 5
• Vascular access site complications: Expanding hematoma, absent distal pulses, severe bleeding 5
• Signs of cardiac tamponade: Hypotension, elevated JVP, muffled heart sounds, pulsus paradoxus 5
• Acute respiratory distress: Oxygen saturation <90% despite supplemental oxygen, pulmonary edema 8
• Oliguria/anuria: Urine output <0.5 mL/kg/hr for >2 hours 8

---

Reassessment and Ongoing Nursing Management

First 24-48 hours:

• Continuous telemetry monitoring for arrhythmias and conduction disturbances 5
• Serial ECGs to assess for conduction changes (compare to baseline) 5
• Daily echocardiography if clinically indicated (assess valve function, paravalvular leak) 5
• Serial hemoglobin/hematocrit to monitor for bleeding 8
• Daily creatinine and electrolytes to assess renal function 8
• Neurological assessments every 4 hours for first 24 hours, then per protocol 5

48 hours to discharge:

• Mobilization: Progressive ambulation as tolerated once vascular access site stable 8
• Medication reconciliation: Ensure dual antiplatelet therapy (aspirin + P2Y12 inhibitor for 3-6 months, then aspirin alone per protocol) 5
• Patient education:
  • Signs/symptoms of complications (chest pain, shortness of breath, neurological changes, access site bleeding) 7
  • Medication adherence (antiplatelet therapy, heart failure medications) 7
  • Activity restrictions (avoid heavy lifting >10 lbs for 1 week, driving restrictions per institutional protocol) 7
  • Follow-up appointments (cardiology, primary care) 7
  • Endocarditis prophylaxis education 7

Long-term follow-up:

• Echocardiography at 30 days, 1 year, then annually to assess valve function and durability 2
• Clinical assessment for symptom improvement, functional status, quality of life 2
• Monitoring for valve degeneration and planning for potential future reinterventions (TAVR-in-TAVR or surgical valve replacement) 6

---

Documentation

Pre-procedure documentation:

• Baseline vital signs, neurological assessment, vascular assessment (distal pulses) 7
• Informed consent verification 7
• Medication administration (antiplatelet loading, antibiotics) 7
• NPO status and last oral intake 7

Intra-procedure documentation:

• Time of procedure start/end 7
• Vascular access site and closure method 7
• Valve type, size, and deployment details 7
• Hemodynamic parameters throughout procedure 7
• Complications and interventions 7
• Medications administered (anticoagulation, vasopressors, anesthetics) 7

Post-procedure documentation:

• Vital signs (every 15 minutes x 1 hour, then hourly x 4 hours, then per protocol) 7
• Vascular access site assessment (appearance, bleeding, hematoma, distal pulses) 7
• Neurological assessment (mental status, motor/sensory function) 7
• Cardiac rhythm and conduction (ECG findings, pacemaker function if applicable) 7
• Fluid balance (intake/output, urine output) 7
• Pain assessment and management 7
• Complications and interventions 7
• Patient/family education provided 7

Discharge documentation:

• Discharge medications (antiplatelet therapy, heart failure medications) 7
• Activity restrictions and follow-up appointments 7
• Patient education on signs/symptoms requiring immediate medical attention 7
• Participation in STS/ACC TVT Registry for quality assurance and outcomes tracking 1